Edition:
United States

Laboratory Corporation of America Holdings (LH.N)

LH.N on New York Stock Exchange

172.08USD
21 Sep 2018
Change (% chg)

$-0.09 (-0.05%)
Prev Close
$172.17
Open
$172.57
Day's High
$173.91
Day's Low
$171.83
Volume
420,144
Avg. Vol
179,133
52-wk High
$190.35
52-wk Low
$147.19

Latest Key Developments (Source: Significant Developments)

LabCorp Reports Q2 Earnings Per Share Of $2.27
Wednesday, 25 Jul 2018 06:55am EDT 

July 25 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES 2018 GUIDANCE.Q2 EARNINGS PER SHARE $2.27.Q2 REVENUE $2.9 BILLION VERSUS I/B/E/S VIEW $2.85 BILLION.Q2 EARNINGS PER SHARE VIEW $2.93 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.35 TO $11.65.Q2 ADJUSTED EARNINGS PER SHARE $2.98.LABCORP - 2018 FREE CASH FLOW GUIDANCE OF $1.1 BILLION TO $1.2 BILLION.FY2018 EARNINGS PER SHARE VIEW $11.57 -- THOMSON REUTERS I/B/E/S.LABCORP - RECORDED RESTRUCTURING CHARGES, SPECIAL ITEMS, AND AMORTIZATION WHICH TOGETHER TOTALED $94.3 MILLION IN QUARTER.LABCORP SEES REVENUE GROWTH OF 10.5% TO 11.5% IN 2018 OVER 2017 REVENUE OF $10.31 BILLION.FY2018 REVENUE VIEW $11.47 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Asymchem Laboratories Tian Jin signs strategic cooperation framework agreement with Covance
Wednesday, 6 Jun 2018 11:50pm EDT 

June 7(Reuters) - Asymchem Laboratories Tian Jin Co Ltd <002821.SZ>:Says it signed a strategic cooperation framework agreement with Covance Inc, regarding new drug development related cooperation.  Full Article

Labcorp And Unilabs Announced Strategic Collaboration To Provide Expanded Global Development Companion Diagnostics
Friday, 1 Jun 2018 08:00am EDT 

June 1 (Reuters) - Laboratory Corporation of America Holdings ::CO, UNILABS ANNOUNCED STRATEGIC COLLABORATION TO PROVIDE EXPANDED GLOBAL DEVELOPMENT AND DELIVERY OF COMPANION DIAGNOSTICS.TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED.COMPANIES EXPECT FIRST APPLICATION OF PROCESSES WILL BE IN ONCOLOGY, PARTICULARLY IMMUNO-ONCOLOGY.  Full Article

LabCorp To Become A Preferred National Laboratory For Aetna
Friday, 25 May 2018 07:15am EDT 

May 25 (Reuters) - Laboratory Corporation of America Holdings ::LABCORP TO BECOME A PREFERRED NATIONAL LABORATORY FOR AETNA.LABCORP - CO, AETNA EXTENDED, EXPANDED EXISTING AGREEMENT, MAKING CO PREFERRED NATIONAL LABORATORY FOR SUBSTANTIALLY ALL AETNA MEMBERS FROM JAN 1, 2019.  Full Article

LabCorp Says CEO David King's FY 2017 Total Compensation Was $11.6 Mln
Friday, 30 Mar 2018 04:55pm EDT 

March 30 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP SAYS CEO DAVID KING'S FY 2017 TOTAL COMPENSATION WAS $11.6 MILLION INCLUDING $6.7 MILLION OF STOCK AWARDS - SEC FILING.  Full Article

Laboratory Corp Says Co, Appalachian Regional Healthcare Entered Multi-Year, Comprehensive Laboratory Partnership‍​
Thursday, 22 Mar 2018 09:52am EDT 

March 22 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP - CO, APPALACHIAN REGIONAL HEALTHCARE ENTERED MULTI-YEAR, COMPREHENSIVE LABORATORY PARTNERSHIP‍​.  Full Article

Interpace Diagnostics Announces Expansion Of Labcorp National Agreement
Tuesday, 20 Mar 2018 08:00am EDT 

March 20 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS ANNOUNCES EXPANSION OF LABCORP NATIONAL AGREEMENT.INTERPACE DIAGNOSTICS - AGREEMENT WITH LABCORP TO FURTHER EXPAND CO'S NETWORK OF CYTOLOGY PROVIDERS IN SUPPORT OF ITS THYROID MOLECULAR BUSINESS UNIT​.INTERPACE DIAGNOSTICS - ‍ UNDER NEW AGREEMENT, PHYSICIANS WILL BE ABLE TO ORDER BOTH THYROID BIOPSY ANALYSIS AND MOLECULAR TESTING FROM INTERPACE​.  Full Article

Covance Forms Immunology & Immunotoxicology Unit Focused On Biologic Drug Development
Friday, 9 Mar 2018 08:45am EST 

March 9 (Reuters) - Laboratory Corporation Of America Holdings ::COVANCE FORMS IMMUNOLOGY & IMMUNOTOXICOLOGY UNIT FOCUSED ON BIOLOGIC DRUG DEVELOPMENT.LABCORP - COVANCE DRUG DEVELOPMENT BUSINESS HAS FORMED A GLOBAL IMMUNOLOGY AND IMMUNOTOXICOLOGY UNIT.  Full Article

Labcorp Says On Track To Deliver $150 Mln In Cumulative New Revenue From Covance Acquisition Through 2018‍​
Tuesday, 6 Mar 2018 08:25am EST 

March 6 (Reuters) - Laboratory Corporation Of America Holdings LH.N::LABCORP - ON TRACK TO DELIVER $150 MILLION IN CUMULATIVE NEW REVENUE FROM COVANCE ACQUISITION THROUGH 2018 - SEC FILING‍​.  Full Article

LabCorp Reports Q4 Earnings Per Share $6.81
Tuesday, 6 Feb 2018 06:57am EST 

Feb 6 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP ANNOUNCES RECORD 2017 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2018 GUIDANCE.Q4 EARNINGS PER SHARE $6.81.Q4 REVENUE ROSE 13.2 PERCENT TO $2.7 BILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.30 TO $11.70.Q4 ADJUSTED EARNINGS PER SHARE $2.45.LABCORP SEES 2018 FREE CASH FLOW OF $1.1 BILLION TO $1.2 BILLION.Q4 EARNINGS PER SHARE VIEW $2.38, REVENUE VIEW $2.69 BILLION -- THOMSON REUTERS I/B/E/S.BACKLOG FOR COVANCE DRUG DEVELOPMENT AT END OF QUARTER WAS $7.13 BILLION.LABCORP SEES 2018 REVENUE GROWTH OF 9.5% TO 11.5% OVER 2017 RESTATED REVENUE OF $10.42 BILLION.‍DURING QUARTER, RECORDED A NET BENEFIT OF $519.0 MILLION IN NET EARNINGS, OR $5.00 PER SHARE, DUE TO IMPLEMENTATION OF TAX LAW​.EXPECTS ABOUT $2.8 BILLION OF BACKLOG IN COVANCE DRUG DEVELOPMENT TO CONVERT INTO REVENUE IN NEXT TWELVE MONTHS.FY2018 EARNINGS PER SHARE VIEW $10.79, REVENUE VIEW $11.03 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article